Business Wire

Payroc Signs Definitive Agreement to Acquire BlueSnap

31.7.2025 12:00:00 CEST | Business Wire | Press Release

Share

Payroc WorldAccess, LLC a leading North American merchant acquirer and payment technology provider, today announced the signing of a definitive agreement to acquire BlueSnap, a Boston-based global payment orchestration and AR automation platform. This strategic acquisition unites Payroc's direct-connect acquiring infrastructure across the U.S., Canada, and Puerto Rico, and transforms Payroc’s capabilities by adding BlueSnap’s robust global and enterprise capabilities. The transaction is expected to close in Q3 2025 and is subject to regulatory approval and other customary items.

Transaction Overview & Strategic Highlights

The acquisition creates a unified acquiring powerhouse that offers both end-to-end global card acquiring and eBanking processing capabilities to merchants, ISVs, and embedded technology partners, including:

  • Global CNP Leadership & Routing Optimization: Accept card-not-present, electronic check and alternative payments in 47 countries, 100+ currencies, and 36+ local methods through a single API. BlueSnap’s intelligent routing and fraud prevention tools improve authorization rates and reduce cross-border costs.
  • AR Automation & Cash Flow Efficiency: Accelerate receivables with embedded invoicing, subscription billing, and automated reconciliation. Real-time dashboards and out-of-the-box workflows simplify billing and collections.
  • Enterprise-Grade Scale & Partner Ecosystem: Trusted by global enterprises and integrated with leading ISVs, ERP platforms, and embedded fintechs.
  • Global Footprint & Compliance Excellence: Local acquiring, combined card and electronic check, dynamic and FX currency conversion, routing and interchange optimization, consolidated and detailed reporting, and managed clearing ensures cost-effective processing and regulatory compliance worldwide.

Leadership Commentary

“Integrating BlueSnap’s orchestration layer with Payroc’s direct-connect network transforms our ability to serve merchants and ISVs at scale,” said Jim Oberman, Chief Executive Officer of Payroc. “This transaction dramatically expands our global footprint and the breadth of capabilities we can bring to our customers and partners. More importantly, we are impressed with the BlueSnap team - our shared culture and vision aligns with Payroc’s ongoing commitment to deliver a more efficient, intelligent, and global payments experience.”

“Joining Payroc gives BlueSnap’s customers direct access to industry-leading acquiring relationships and a broader partner ecosystem,” said Henry Helgeson, Chief Executive Officer of BlueSnap. “Together, we’ll empower businesses to scale payments both domestically and globally, automate receivables, and innovate faster than ever.”

Transaction Advisors

  • Payroc was advised by Troutman Pepper, Locke, and White & Case LLP as legal counsel.

  • BlueSnap was advised by TD Securities and William Blair as financial advisors, and Goodwin Procter LLP as legal counsel.

About Payroc

Payroc WorldAccess, LLC is a high-growth merchant acquirer, processor, and integrated payments provider offering advanced sales enablement and global payment processing technology. Payroc delivers proprietary, innovative, and full-service acquiring solutions supported by key card brand sponsorships and bank partnerships.

Payroc, through its subsidiaries, is a registered Visa third-party processor, Visa ISO, Mastercard third-party and MSP, payment facilitator, and encryption support organization for Fifth Third Bank, National Association, and is registered in Canada with Peoples Trust Company and Oriental Bank in Puerto Rico, among others.

Learn more at www.payroc.com.

About BlueSnap

BlueSnap is a global payment orchestration platform that helps businesses accept payments worldwide and optimize their revenue operations. With a single integration, BlueSnap supports online and mobile sales, marketplaces, subscriptions, invoice payments, and manual orders through a virtual terminal. The platform includes access to 100+ payment types, built-in fraud prevention, chargeback management, and automated accounts receivable tools.

Learn more at www.bluesnap.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250731993513/en/

Contacts

Media Contact: Alex McCandless
alex.mccandless@payroc.com | 404-907-7623

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye